Wave rides new Phase 2 DMD da­ta as it sets sights on ac­cel­er­at­ed ap­proval

Wave Life Sci­ences said new Phase 2 bio­mark­er da­ta for its ex­on-skip­ping ther­a­py are promis­ing for cer­tain pa­tients with Duchenne mus­cu­lar dy­s­tro­phy, and it plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER